An interventional study of Conventional exercises and Core stabilization exercises in addition to conventional exercises in Acute Lymphoblastic Leukemia, sponsored by Karamanoğlu Mehmetbey University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Karamanoğlu Mehmetbey University · Not applicable, Interventional, and Treatment
Among 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey — 6 open to participants now, 11 under way, 5 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Turkey.
Among the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey, this one is the 25th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 with no phase, and was the 34th registered.
2,584 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →6 of the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey are open now. Recruiting first, the newest first:
Ege University · Sites in Turkey
Ages 4–12
Ascentage Pharma Group Inc. · Sites in Turkey, United States, Australia and 9 more countries
Ages 18+
St. Anna Kinderkrebsforschung · Sites in Turkey, Argentina, Australia and 28 more countries
Ages 1 mo–18 yrs
Izmir Katip Celebi University · Sites in Turkey
Ages 12–15 · Healthy volunteers
Fenerbahce University · Sites in Turkey
Ages 8–14 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 5 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 11 · Phase 4 1
First in 1995; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 102 across the 31 interventional studies, 83 across the 7 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 38 have an industry lead sponsor. The 10 most frequent:
Karamanoğlu Mehmetbey University is the lead sponsor of 69 studies on the registry; 19 are open to participants now.
Karamanoğlu Mehmetbey University has 1 study filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04521231AmgenA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | 2027-11-24 |
Among the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate the effects of core stabilization exercises applied in addition to the conventional exercise program on physical function, functional muscle strength, functional exercise capacity, postural control and fatigue in children with acute lymphoblastic leukemia receiving maintenance treatment.
Participants will be divided into two groups; the first group will be given a conventional exercise program, while the second group will be given core stabilization exercises in addition to the conventional exercise program.
Acute Lymphoblastic Leukemia (ALL) is a malignancy resulting from the abnormal proliferation of lymphoid cells that can invade the bone marrow, blood, and extramedullary regions, and it is the most common malignancy in childhood. Specific chemotherapy-related problems are frequently observed in children with ALL. These include a reduction in cardiopulmonary fitness, balance, posture, proximal muscle strength, and flexibility, as well as postural control issues and functional mobility impairments, in addition to fatigue.
The aim of this study is to investigate the effects of core stabilization exercises, applied in addition to a conventional exercise program, on physical function, functional muscle strength, functional exercise capacity, postural control, and fatigue in children with Acute Lymphoblastic Leukemia undergoing maintenance therapy.
Participants will be divided into two groups: the first group will follow a conventional exercise program, while the second group will receive core stabilization exercises in addition to the conventional program. All participants will be randomly assigned to the groups using the software available at http://www.randomizer.org. The exercise sessions will be conducted three times a week for a total of 8 weeks, with 24 sessions in total. Demographic information will be recorded for participants who agree to take part in the study and meet the inclusion criteria. The scales and tests designed to assess the participants' physical function, functional muscle strength, functional exercise capacity, postural control, and fatigue will be administered both before and after the study.
The criteria were revised on the registry on Oct 7, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exercises will be applied to the participants participating in the study 3 days a week, 8 weeks, and 24 sessions in total.
Other: Conventional exercises
Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
Other: Core stabilization exercises in addition to conventional exercises
Aerobic exercise and stretching exercises will be applied in the conventional exercise program. A 20-30 minute walking will be done as aerobic exercise. Stretching exercises will be done for major muscle groups in 3 sets and 10 repetitions.
In addition to the conventional exercise program, core stabilization exercises will be applied. During the exercises, participants will be trained on neutralizing the spine and working the transverse abdominis and multifidus muscles, correct postural control, and performing the exercises with diaphragmatic breathing.
Timed Up and Go Test (TUG)
This test aims to evaluate the physical function.
Time frame: Before 8 weeks of treatment
Timed Up and Go Test (TUG)
This test aims to evaluate the physical function.
Time frame: After 8 weeks of treatment
Sit-up Test
This test aims to evaluate the functional muscle strength
Time frame: Before 8 weeks of treatment
Sit-up Test
This aims to evaluate the functional muscle strength.
Time frame: After 8 weeks of treatment
6-Minute Walk Test
This test aims to evaluate the functional exercise capacity.
Time frame: Before 8 weeks of treatment
6-Minute Walk Test
This test aims to evaluate the functional exercise capacity.
Time frame: After 8 weeks of treatment
Balance Error Scoring System
This test aims to evaluate the postural control.
Time frame: Before 8 weeks of treatment
Balance Error Scoring System
This test aims to evaluate the postural control.
Time frame: After 8 weeks of treatment
Pediatric Quality of Life Multidimensional Fatigue Scale
This scale aims to evaluate the fatigue in pediatric patients.
Time frame: Before 8 weeks of treatment
Pediatric Quality of Life Multidimensional Fatigue Scale
This scale aims to evaluate the fatigue in pediatric patients.
Time frame: After 8 weeks of treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Mar 2026, 14 months.
Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's 14 months is below that.
Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Feb 2026 → Mar 2026 and completion Feb 2026 → Mar 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Karamanoğlu Mehmetbey University